If there is clinical success the SP will go way above $1. I wouldn't be stuffed full of 80c options if I thought that. Pfizer sell US$10b of Eylea peryear and sozinibercept combo will eclipse all comers. Why woudln't Pfizer pay OPT US$1b per year to add a sozinibercept to each treatment and stay ahead of the pack? Do the math on US$1b per year profit. At PE of 10 that US$10b = $16? Not saying that will happen but there's the ball park.
Ann: Opthea Completes Placement & Institutional Entitlement Offer, page-32
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.025(6.49%) |
Mkt cap ! $492.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 41.0¢ | 38.5¢ | $430.2K | 1.078M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 66868 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 146958 | 10 |
View Market Depth
| Last trade - 15.08pm 24/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |